Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
| Autor: | Zhangjun Song, Zheng Zhao, Yong Yuan, Pan Yu, Haifeng Sun, Xiaomin Yang, Xuwei Wang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Lung Crizotinib ROS1 Fusion business.industry Treatment of lung cancer medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Cancer research medicine Anaplastic lymphoma kinase Adenocarcinoma Pharmacology (medical) Lung cancer business Lymph node medicine.drug |
| Zdroj: | OncoTargets and Therapy. 10:4129-4133 |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s136297 |
| Popis: | ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|